Drug Trial Radar · NCT04185883
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
610
Actual
Start
Dec 17, 2019
Primary completion
Dec 17, 2026
Study completion Dec 5, 2027
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Dec 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Conditions
- Advanced Solid Tumors
- Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
SotorasibDrug
Sotorasib administered orally as a tablet.
TrametinibDrug
Trametinib administered orally as a tablet.
RMC-4630Drug
RMC-4630 administered orally as a capsule.
AfatinibDrug
afatinib administered orally as a tablet.
PembrolizumabDrug
pembrolizumab administered as an intravenous (IV) infusion.
PanitumumabDrug
Panitumumab administered as an IV infusion.
Carboplatin, pemetrexed, docetaxel, paclitaxelDrug
Carboplatin, pemetrexed, docetaxel administered as an IV infusion.
AtezolizumabDrug
Atezolizumab administered as an IV injection.
PalbociclibDrug
Palbociclib administered orally as a tablet.
MVASI® (bevacizumab-awwb)Drug
MVASI® (bevacizumab-awwb) administered as an IV infusion.
TNO155Drug
TNO155 administered orally as a capsule.
IV Chemotherapy (Regimen 1)Drug
Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
IV Chemotherapy (Regimen 2)Drug
IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.
BI 1701963Drug
BI 1701963 administered orally
AMG 404Drug
AMG 404 administered as an IV infusion.
EverolimusDrug
Everolimus administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: 12 Months
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: 12 Months
- Number of Participants with Treatment-related Adverse EventsTime frame: 12 Months
- Number of Participants with Clinically Significant Changes in Vital SignsTime frame: 12 Months
- Number of Participants with Clinically Significant Changes in ECG MeasurementsTime frame: 12 Months
- Number of Participants with Clinically Significant Changes in Laboratory Test ValuesTime frame: 12 Months
Locations
90 sites in 13 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates Professional Corporation
Tucson, Arizona
City of Hope National Medical Center
Duarte, California
University of California San Diego Moores Cancer Center
La Jolla, California
Loma Linda University Cancer Center
Loma Linda, California
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California
University of California Davis Medical Center
Sacramento, California
University of California San Francisco Mission Bay Campus
San Francisco, California
University of California Los Angeles
Santa Monica, California
Rocky Mountain Cancer Centers Denver Midtown
Denver, Colorado
Sarah Cannon Research Institute
Denver, Colorado
Yale New Haven Hospital
New Haven, Connecticut
Norwalk Hospital
Norwalk, Connecticut
Memorial Cancer Institute
Pembroke Pines, Florida
Moffitt Cancer Center
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Johns Hopkins University
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan
Washington University
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Irving Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Levine Cancer Institute
Charlotte, North Carolina
Duke University
Durham, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Providence Portland Medical Center
Portland, Oregon
Oregon Health and Science University
Portland, Oregon
Thomas Jefferson University
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Gibbs Cancer Center and Research Institute - Spartanburg
Spartanburg, South Carolina
Avera Cancer Institute
Sioux Falls, South Dakota
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.